Optimization of programmed death Ligand-1 73-10 clone immunohistochemical protocol on urothelial carcinomas
References
- Germanà E, Pepe L, Pizzimenti C, Ballato M, Pierconti F, Tuccari G, et al. Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications. Int J Mol Sci 2024;25. https://doi.org/10.3390/ijms25126750.
- Cojocaru I, Guliciuc M, Cojocaru E, Serban C, Pascaru G, Borz MB, et al. A Review of the Latest Evidence on Prognostic Factors in Locally Advanced and Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. Medicina (Kaunas) 2025;62:46. https://doi.org/10.3390/medicina62010046.
- Soares A, Bourlon MT, Wong A, Joshi A, Jardim D, Korbenfeld E, et al. Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion. Clin Genitourin Cancer 2024;22:467–75. https://doi.org/10.1016/j.clgc.2024.01.001.
- Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Annals of Oncology 2022;33:244–58. https://doi.org/10.1016/j.annonc.2021.11.012.
- Shilo K, Shen T, Hammond S, Parwani A V., Li Z, Dayal S, et al. Performance Analysis of Leica Biosystems Monoclonal Antibody Programmed Cell Death Ligand 1 Clone 73-10 on Breast, Colorectal, and Hepatocellular Carcinomas. Appl Immunohistochem Mol Morphol 2024;32:255–63. https://doi.org/10.1097/PAI.0000000000001202.
- Ilié M, Ngo-Mai M, Long-Mira E, Lassalle S, Butori C, Bence C, et al. Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients. J Vis Exp 2018;2018. https://doi.org/10.3791/58082.
- NordiQC - Immunohistochemical Quality Control n.d. https://www.nordiqc.org/epitope.php?id=107 (accessed April 1, 2026).
- Loghin A, Nechifor-Boilă A, Borda A, Nechifor-Boilă IA, Voidazan S, Decaussin-Petrucci M. Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263. Virchows Arch 2022;480:303–13. https://doi.org/10.1007/s00428-021-03215-1.
- Svenningsen C, Technologies Inc A. PD-L1 IHC 22C3 pharmDx Interpretation Manual-Urothelial Carcinoma CE-IVD-marked for in vitro diagnostic use. n.d.
- [Stenehjem DD, Tran D, Nkrumah MA, Gupta S. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco Targets Ther 2018;11:5973. https://doi.org/10.2147/OTT.S135157.
- Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol 2024;143. https://doi.org/10.1016/j.intimp.2024.113365.
- Kim SW, Roh J, Park CS. Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips. J Pathol Transl Med 2016;50:411. https://doi.org/10.4132/jptm.2016.08.08.
- Rahman MA, Sultana N, Ayman U, Bhakta S, Afrose M, Afrin M, et al. Alcoholic fixation over formalin fixation: A new, safer option for morphologic and molecular analysis of tissues. Saudi J Biol Sci 2021;29:175. https://doi.org/10.1016/j.sjbs.2021.08.075.
- Grizzle WE. Models of Fixation and Tissue Processing. Biotech Histochem 2009;84:185. https://doi.org/10.3109/10520290903039052.
- Shojaeian S, Lay NM, Zarnani A-H, Shojaeian S, Lay NM, Zarnani A-H. Detection Systems in Immunohistochemistry. Immunohistochemistry - The Ageless Biotechnology 2018. https://doi.org/10.5772/intechopen.82072.
- Janardhan KS, Jensen H, Clayton NP, Herbert RA. Immunohistochemistry in Investigative and Toxicologic Pathology. Toxicol Pathol 2018;46:488–510. https://doi.org/10.1177/0192623318776907.
- Howat WJ, Lewis A, Jones P, Kampf C, Pontén F, van der Loos CM, et al. Antibody validation of immunohistochemistry for biomarker discovery: Recommendations of a consortium of academic and pharmaceutical based histopathology researchers. Methods 2014;70:34. https://doi.org/10.1016/j.ymeth.2014.01.018.
- Magaki S, Hojat SA, Wei B, So A, Yong WH. An Introduction to the Performance of Immunohistochemistry. Methods Mol Biol 2019;1897:289. https://doi.org/10.1007/978-1-4939-8935-5_25.
- Tsutsumi Y. Pitfalls and Caveats in Applying Chromogenic Immunostaining to Histopathological Diagnosis. Cells 2021;10. https://doi.org/10.3390/cells10061501.
- Ðordević M, Životić M, Škodrić SR, Ostojić JN, Lipkovski JM, Filipović J, et al. Effects of Automation on Sustainability of Immunohistochemistry Laboratory. Healthcare 2021;9:866. https://doi.org/10.3390/healthcare9070866.
- View of Methods of Immunohistochemistry and Its Applications: A Review n.d. https://journalajmpcp.com/index.php/AJMPCP/article/view/357/818 (accessed May 4, 2026).
- [Torga T, Suutre S, Kisand K, Aunapuu M, Arend A. Comparison of Antigen Retrieval Methods for Immunohistochemical Analysis of Cartilage Matrix Glycoproteins Using Cartilage Intermediate Layer Protein 2 (CILP-2) as an Example. Methods and Protocols 2024, Vol 7, 2024;7. https://doi.org/10.3390/MPS7050067.
- Wang H, Luo X, Qiang X, Dai X. Heat-induced antigen retrieval by using Tris-EDTA solution destroys nuclear structure in certain tissues. Biochem Biophys Rep 2026;45:102443. https://doi.org/10.1016/J.BBREP.2026.102443.
DOI: https://doi.org/10.62838/amsm-2026-0020 | Journal eISSN: 2668-7763 (formerly 2247-6113) | Journal ISSN: 2668-7755
Language: English
Page range: 227 - 234
Submitted on: May 5, 2026
Accepted on: Jun 24, 2026
Published online: Sep 30, 2026
Published in print: Sep 1, 2026
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Lorena Solovăstru, Ioan Alin Nechifor-Boilă, Angela Borda, Andrada Loghin, Adela Nechifor-Boilă, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.